Search results for "ASPIRIN"

showing 10 items of 146 documents

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After A…

2017

Abstract: The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originall…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier Estimate030204 cardiovascular system & hematologyVentricular Function Leftchemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineRetrospective StudieRisk FactorsClinical endpointOdds Ratiozofenopril030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as Topicleft ventricular dysfunctionMortality ratePharmacology; Cardiology and Cardiovascular MedicineMiddle AgedZofenoprilHospitalizationTreatment OutcomeCardiologyOriginal ArticleDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugRamiprilmedicine.medical_specialtyLogistic ModelTime FactorSystoleacute myocardial infarctionramiprilDisease-Free SurvivalDrug Administration ScheduleFollow-Up Studie03 medical and health sciencesStatistical significanceInternal medicineEarly Medical InterventionmedicineHumansIntensive care medicineAgedRetrospective StudiesPharmacologyChi-Square DistributionAspirinbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratioRecovery of Functionmedicine.diseaseConfidence intervalLogistic ModelschemistryClinical Trials Phase III as Topicbusinessacetyl salicylic acidFollow-Up StudiesJournal of Cardiovascular Pharmacology
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct

Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure

2012

Aims: The purpose of this study was to evaluate the effect of transient local myocardial gene transfer of iNOS on cardiac function in a large mammal animal model of heart failure induced by chronic ischemia. Methods: Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs. Upon demonstration of heart failure, eight animals were treated with liposome-mediated iNOS-gene-transfer by local intramyocardial injection; eight animals received a sham procedure to serve as control. Results: The transmurality of late enhancement (control: 46.4%, iNOS: 35.9%; p < 0.05) was significantly decreased in the ischemic area in the iNOS-treated group. Wall thickness at end-…

MaleCardiac function curvemedicine.medical_specialtyTiclopidineSwinePhysiologySus scrofaMyocardial IschemiaIschemiaContrast MediaNitric Oxide Synthase Type IIGadoliniumCoronary AngiographyContractilityRandom AllocationVentricular Dysfunction LeftGenes ReporterFibrosisPhysiology (medical)Internal medicineGenes SyntheticmedicineAnimalsTiclopidineHeart FailureDrug CarriersAspirinAspirinmedicine.diagnostic_testbusiness.industryCoronary StenosisAnticoagulantsMagnetic resonance imagingGenetic TherapyHematologymedicine.diseaseFibrosisMagnetic Resonance ImagingMyocardial ContractionClopidogrelDisease Models AnimalHeart failureLiposomesCardiologyFemaleStentsCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, li…

2018

Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.

MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studies
researchProduct

Acetylsalicylic acid reduces heat responses in rat nociceptive primary sensory neurons – evidence for a new mechanism of action

2002

Acetylsalicylic acid (ASA) is thought to exert its peripheral analgesic effects via inhibition of cyclooxygenase. We now studied the effects of ASA on heat responses in primary nociceptive neurons by whole-cell patch-clamp and calcium microfluorimetry experiments. Heat-evoked inward currents in acutely dissociated rat dorsal root ganglion neurons were significantly reduced by ASA in a dose-dependent and reversible manner (IC(50) 375 nM, Hill slope -2.2, maximum effect 55%). Heat-evoked calcium transients (measured with FURA-2) were reversibly reduced by 53+/-14% (P0.05) by co-application of 1 microM ASA. The low IC(50) value, the rapid occurrence, and the reversibility of the observed effec…

MaleHot TemperaturePatch-Clamp TechniquesPainchemistry.chemical_elementCalciumPharmacologyIon ChannelsMembrane PotentialsRats Sprague-Dawleychemistry.chemical_compoundDorsal root ganglionGanglia SpinalmedicineAnimalsCyclooxygenase InhibitorsThermosensingCalcium SignalingNeurons AfferentPatch clampCells CulturedAspirinDose-Response Relationship DrugGeneral NeuroscienceNociceptorsMicrofluorimetryElectric StimulationSensory neuronRatsmedicine.anatomical_structurechemistryMechanism of actionBiochemistryCapsaicinNociceptorCalciumCapsaicinmedicine.symptomSignal TransductionNeuroscience Letters
researchProduct

Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY regis…

2015

Background and objective: Management of outpatients with stable coronary artery disease (CAD) is important in secondary prevention. The objective was to describe differences in the characteristics of CAD patients in Latvia compared with other countries. Materials and methods: CLARIFY is an ongoing international, prospective, observational, longitudinal registry of outpatients with CAD. Data regarding treated outpatients with established CAD from the CLARIFY registry in Latvia (n = 120) were compared with those from the rest of Central-Eastern Europe (CEE) (n = 2888) and worldwide (n = 33,163). Results: Patients in Latvia had a larger waist circumference (101 [95–109] vs. 99 [91–106] in CEE,…

MaleMedicine (General)medicine.medical_specialtyWaistmedicine.medical_treatmentDiastoleCoronary artery disease; Latvia; Prevention; Risk factors; Medicine (all)Coronary artery diseaseBody Mass IndexNOCoronary artery diseaseR5-920Percutaneous Coronary InterventionGeneral & Internal MedicineInternal medicineSecondary PreventionmedicineHumansProspective StudiesRegistriesCoronary artery disease; Latvia; Risk factors; PreventionProspective cohort studyAgedMedicine(all)AspirinAspirinbusiness.industryPreventionMedicine (all)CLARIFY registry investigatorsPercutaneous coronary interventionMiddle Agedmedicine.diseaseLatviaBlood pressureRisk factorsEvidence-Based PracticeAutomotive EngineeringCardiologyFemaleWaist CircumferencebusinessBody mass indexmedicine.drugMedicina
researchProduct

Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia.

2007

To assess the effects of acetylsalicylic acid (ASA) on glutamate and interleukin-6 (IL-6) release in the striatum of rats suffering from cerebral ischemia, we used the microdialysis technique with probes implanted 2 h prior to stroke onset. A total of 36 rats were randomly assigned to either temporary (90 min, n = 18) or permanent (n = 18) middle cerebral artery occlusion (MCAO). Animals received either a bolus of 40 mg/kg ASA or saline as control 30 min after stroke onset. Permanent MCAO led to large infarct volumes with no differences between treatment with ASA (239.8 ± 4.1 mm3) and saline (230.1 ± 3.9 mm3, p = 0.15). In contrast, ASA therapy in temporary ischemia (87.2 ± 6.2 mm3) reduced…

MaleMicrodialysisTime Factorsmedicine.medical_treatmentIschemiaGlutamic AcidEnzyme-Linked Immunosorbent AssayNeuroprotectionBrain IschemiaBrain ischemiaBolus (medicine)Developmental NeurosciencemedicineAnimalscardiovascular diseasesRats WistarSalinePeroxidaseAnalysis of VarianceAspirinbusiness.industryInterleukin-6PenumbraGlutamate receptorCerebral Infarctionmedicine.diseaseRatsDisease Models AnimalNeuroprotective AgentsNeurologyGene Expression RegulationIschemic Attack TransientAnesthesiabusinessProto-Oncogene Proteins c-fosExperimental neurology
researchProduct

Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study.

2006

The effect of aspirin on dopaminergic neuronal damage induced by in vivo infusion of 1-methyl-4-phenylpiridinium iodide (MPP(+)) and 6-hydroxydopamine (6-OHDA) was studied in rats, using microdialysis. Rat striata were perfused with 1 mM MPP(+) or 6-OHDA for 10 min, causing peak levels of dopamine (DA) in the dialytic fluid, after 40 min. After 24 h, 1 mM MPP(+) was perfused again for 10 min and DA levels measured in the dialytic fluid, as an index of neuronal cell integrity. Pretreatment with Aspidol (lysine acetylsalicylate), 180 mg/kg i.p., 1 h before MPP(+) or 6-OHDA perfusion, did not modify DA extracellular output, on day 1, but restored MPP(+)-induced DA release on day 2, indicating …

MaleMicrodialysisTyrosine 3-MonooxygenaseDopamineMicrodialysisNeurotoxinsPharmacologyNeuroprotectionSettore BIO/09 - FisiologiaRats Sprague-Dawleychemistry.chemical_compoundIn vivoHydroxybenzoatesNeurotoxinAnimalsDrug InteractionsMolecular BiologyChromatography High Pressure LiquidNeuronsAnalysis of VarianceAspirinGeneral NeuroscienceMPTPDopaminergicImmunohistochemistryCorpus StriatumRatsNeuroprotective Agentsnervous systemchemistryAnesthesiaNerve DegenerationNeurology (clinical)Aspirin in vivo microdialysisPerfusionOxidopamineDevelopmental Biology
researchProduct

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and manag…

2018

Abstract The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations. Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should…

MalePediatricsReviewPediatricsSeverity of Illness Index0302 clinical medicineRetrospective StudieEpidemiology030212 general & internal medicineDisease management (health)Coronary artery abnormalitieChildrenSocieties MedicalRandomized Controlled Trials as TopicPediatriclcsh:RJ1-570Disease ManagementImmunoglobulins IntravenousGeneral MedicinePrognosisSettore MED/38Treatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMeta-analysisAcute DiseasePractice Guidelines as TopicDisease ProgressionFemaleCoronary artery abnormalitiesAspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki disease;Humanmedicine.medical_specialtyPrognosiMucocutaneous Lymph Node SyndromeRisk Assessment03 medical and health sciences030225 pediatricsSeverity of illnessmedicineHumansRisk factorIntravenous immunoglobulinRetrospective Studiesaspirin; children; coronary artery abnormalities; intravenous immunoglobulin; Kawasaki disease; pediatrics perinatology and child healthAspirinKawasaki diseasebusiness.industrylcsh:PediatricsRetrospective cohort studymedicine.diseaseImmunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseDifferential diagnosisbusiness
researchProduct